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CASE STUDY
Is it bowel-associated dermatosis- 
arthritis syndrome induced by small intestinal 
bacteria overgrowth?
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Abstract 
Introduction: Bowel-associated dermatosis-arthritis syndrome is rare systemic diseases characterized by a pro-
drome of fever, chills, and influenza-like symptoms with subsequent skin eruptions, myalgias, and polyarthralgias. It is 
reported to be occurred in Intestinal bypass surgery and inflammatory bowel disease.
Case description: Herein, we described a 29-years-old man with Bowel-associated dermatosis-arthritis syndrome. 
He had no history of gastrointestinal surgery and inflammatory bowel disease. Distribution of the gut bacterial flora 
showed small intestinal bacterial overgrowth.
Discussion and Evaluation: It is rarely form as Non-intestinal bypass road and non-inflammatory bowel disease was 
induced by small intestinal bacteria overgrowth.
Conclusions: We concluded that Immuno-inflammatory response to overgrowth of intestinal bacterial antigen 
induce the clinical symptoms of bowel-associated dermatosis-arthritis syndrome.
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Background
Bowel-associated dermatosis-arthritis syndrome 
(BADAS) was first described by Ely in 1980s with charac-
teristics of fever, chills, and influenza-like symptoms with 
subsequent skin eruptions, myalgias, and polyarthral-
gias (Ely PH.1980). It is called as short-bowel syndrome 
since the occurrence rate among patients of jejuno-
ileum bypass bariatric surgery is over 20  %. BADAS is 
reported to be occurred in ileoanal anastomosis, bili-
opancreatic diversion as well as Billroth II gastrectomy. 
Jorizzo described four cases (Jorizzo et  al. 1983), these 
patients had the same clinical manifestations with short-
bowel syndrome, however, they had never received any 
operations which mentioned above. The only common 
point of these patients was that they all had gastrointes-
tinal disease and similar cases had been continuously 
reported afterwards (Delaney et al. 1989; Kemp and Gin 
1990; Geary et  al. 1999; Cox and Palmer 2003). Schol-
ars believed that it was a complication of inflammatory 
bowel disease and put forward the concept of bowel-
associated dermatosis-arthritis syndrome (BADAS) to 
cover the non-intestinal bypass short-bowel syndrome. 
A number of literatures reported that SIBO was involved 
in the pathogenesis of the disease. Short-bowel syndrome 
predisposes the patient to Small Intestine Bacterial Over-
growth (SIBO) (Goulet and Joly 2010). It has been shown 
that patients with Crohn’s  disease  (CD) have a higher 
risk of SIBO development (Greco et al. 2015). Herein, we 
described a patient with BADAS induce by small intesti-
nal bacterial overgrowth.
Case presentation
A 29-year-old man complained of joint pain, fever, rash 
and intermittent diarrhea for about a year. One year ago, 
he had arthralgia and swelling in the ankles, knees, wrists 
and digital joints, together with fever (>38.7 °C) and ery-
thematous nodular rashes with diameter of about 1  cm 
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turn up on his limbs,These rashes have vague bounda-
ries with the normal skin nearby (Fig.  1). The watery 
and soft stools occurred intermittently, with 3–4 bouts 
a day and 4–5  days a month. He had been diagnosed 
with reactive arthritis. After taking non-steroidal anti-
inflammatory drugs (NSAIDs) such as celecoxib, arthri-
tis, fever and rash were relieved for a short time before 
recurrence. He didn’t undergo gastrointestinal surgery. 
After being admitted to our hospital, his blood cell count, 
urinary analysis and stool routine with occult blood test 
were normal. The erythrocyte sedimentation rate (ESR) 
104  mm/h (0–21  mm/h), C-reactive protein (CRP) 
94.7  mg/L (0–8  mg/l), interleukin-6(IL-6) 123.8  ng/ml 
(0–7  ng/ml) were all increased. HLA-B27 was negative. 
No abnormalities were found in the procalcitonin, blood 
culture, Multiple virus antibody, T-SPOT.TB, tumor 
marker, anti-nuclear antibody (ANA), anti-dsDNA anti-
body (AdsDNA), anti-ENA antibodies, rheumatoid factor 
(RF), anti-CCP, and anti-neutrophil cytoplasmic anti-
bodies (ANCA). Electronic gastrointestinal endoscope 
(FUJINON EVE 400 SERIES VIDEO SYSTEM), results of 
abdomen CT and bone marrow aspiration cytology were 
normal. Distribution of the gut bacterial flora showed 
dysbacteriosis with 10  % klebsiellapneumoniae, 80  % E. 
coli and 10  % peptostreptococcus. The result of SIBO 
test (hydrogen-methane breath test with lactulose as the 
substrate) was positive (Fig. 2). A further skin biopsy was 
taken from a rash on the left lower extremity and Low 
power microscope shows lymphocyte and neutrophile 
granulocyte around deep blood vessels of dermis (Fig. 3). 
He was diagnosed with BADAS (caused by small intesti-
nal bacterial overgrowth). The patient was improved dra-
matically after treatment with doxycycline 0.2 g/day and 
methylprednisolone 40  mg/day for a week. Glucocorti-
coid tapered gradually to withdrawal. The patient was fol-
lowed up for 12 months without recurrent symptoms.
Discussion and evaluation
BADAS is a non-infectious neutrophilic dermatosis with 
prominent of features of rashes and joint pain. Typi-
cal rashes are red spots with diameter of 3–10 mm and 
vague boundaries. The rashes gradually harden in the fol-
lowing 1 or 2 days and turn to papulopustule with diam-
eter of 2–4 mm. The process of this disease could last for 
2–8  days and showed as a self-limited process (Patton 
et al. 2009; Slater et al. 2004; Kawakami et al. 2006). The 
rashes are mainly distributed on the body and limbs (Jor-
izzo et  al. 1983), and they may be featured by pruritus, 
pain or no subjective symptom (Slater et al. 2004). Polyar-
thritis may be involved in patients which had peripheral 
joints like IP joints and wrist joints, however, but there is 
no imageological change, joint destruction or deformity 
(Utsinger 1980). Laboratory indexes such as RF, immune 
globulin and uric acid are all within normal limits, how-
ever, some patients may have elevated cryoglobulin (Pat-
ton et al. 2009). In microbiological examination, both of 
Fig. 1 The picture of red tubercular rashes on both lower limbs. Note: The patient has red tubercular rashes on both lower limbs,erythematous 
nodular rashes with diameter of about 3-10 mm and vague boundaries on his limbs
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blood culture and rash fester culture results are negative 
(Truchuelo et al. 2013). The dermal pathology of BADAS 
is usually the same as acute febrile neutrophilic derma-
tosis (SWEET) syndrome. It mainly shows infiltration of 
mature neutrophile granulocyte in dermis and sometimes 
edema of dermal papilla. It had no fibrinoid necrosis or 
blood vessel infarct, which is the main difference from 
leukocytoclastic vasculitis (Patton et al. 2009; Ashok and 
Kiely 2007). However, other research showed that the 
dermal pathology changes with the development of the 
disease is not an essential condition for diagnosing the 
BADAS (Patton et al. 2009). In the course of clinical diag-
nosis and treatment, BADAS also must be distinguished 
from extra-intestinal manifestations of inflammatory 
bowel disease (Adams and Eksteen 2006; Trikudanathan 
et al. 2012; Marineaţă et al. 2014; Brown et al. 2015).
As the cause is not clear, it is now generally accepted 
that it is an abnormal immune response of residual 
intestine after intestinal survey or abnormal intestine of 
inflammatory bowel disease to the bacterial overgrowth. 
SIBO is defined as nonpathogenic bacteria increase 
over 105cfuin 1 ml of small intestine content. Due to the 
lack of specific symptoms, SIBO is often misdiagnosed. 
In fact, SIBO occurrence is fairly frequent. SIBO might 
present in more than 60 % patients with abdominal pain 
(Siniewicz-Luzenczyk et  al. 2015). In systemic sclero-
sis, 38  % patientswith intestinal complaints were diag-
nosed with SIBO (Tauber et al. 2014). The formation of 
immune complex, access to blood and deposition in tis-
sues and organs are crucial in the occurrence of disease 
which could induce various related clinical symptoms 
(Slater et  al. 2004; Utsinger 1980; Dicken 1986; Jorizzo 
et  al. 1984) and this theory can be indirectly proved by 
the curative effect of antibiotics and glucocorticoid to the 
disease. Glucocorticoid is as the main medicine for this 
disease and antibiotics (metronidazole, tetracycline and 
sulfonamides) are also used with different effects. Resum-
ing the normal anatomy of intestine or curing potential 
gastrointestinal disease also has certain mitigative effect 
(Ashok and Kiely 2007).
About 20 % of patients of jejunoileum bypass bariatric 
surgery are likely to have the symptoms of rash or joint 
pain (Ely 1980). Other non-bypass surgery or disease of 
digestive tract such as inflammatory bowel disease has 
had already been continuously reported, which is sec-
ondary to the BADAS (Cox and Palmer 2003; Patton 
et  al. 2009). In our case, the clinical manifestation and 
dermal pathology of rashes are the same with those dis-
eases mentioned above, however, there is no intestinal 
surgery, nor any evidence of inflammatory bowel disease. 
Only the hydrogen-methane breath test with lactulose as 
the substrate indicates SIBO. The disease may not merely 
Fig. 2 The result of small intestinal bacterial overgrowth (SIBO). Note: 
The result of small intestinal bacterial overgrowth (SIBO) test is posi-
tive. Hydrogen-methane breath test with glucose as the substrate, 
after taking glucose for 1 h, the concentration of H2 reached the peak 
value which implied the bacterial overgrowth in the ileum
Fig. 3 The dermal pathology at rashes. Note: The dermal pathology at rashes manifests lymphocyte and neutrophile granulocyte around the deep 
blood vessels of dermis (rash skin of left limb, HE staining, original magnification 200–400)
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occur among patients of jejuno-ileum bypass bariatric 
surgery and inflammatory bowel disease as mentioned 
in previous literature. Immuno-inflammatory response 
to bacterial antigen may be caused by any factors which 
caused the overgrowth of intestinal bacteria, mediate for-
mation of immune complex and hence induce the clini-
cal symptoms of BADAS. Therefore, whether the patients 
had specific digestive system surgery or medical history, 
as organic or functional factor which may cause intestinal 
bacterial overgrowth should be taken into consideration 
during the clinical diagnosis of physician. Patient with 
only SIBO, non-intestinal bypass road and non-inflam-
matory bowel disease could also be diagnosed as BADAS.
Conclusion
In clinical practice, rheumatologists can easily recognize 
BADAS patients with jejunoileum bypass bariatric sur-
gery or inflammatory bowel disease, and more attention 
should be paid to bacteria translocation, flora imbalance 
and SIBO which may also result in BADAS. Correctly 
understanding the factors that influence the occurrence 
of BADAS will help us getting to understand more about 
diagnosing this relatively rare disease.
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